CHV in the Press:
Immunis Inc a CHV portfolio - Announces Preliminary Results from First-Ever Phase 2 Study of a Secretome-Based Biologic Showing Weight Loss with Preserved Muscle and Improved Gait Speed in Obese Sarcopenic Seniors
Jan 14, 2026
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has closed a $10M Series A First Closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Strategic investor, Continuum Health Ventures, which supports thesis-driven startups at the intersection of health and technology in the digital health and longevity sectors, also joined the round. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy, which is an age, disuse and disease-associated condition experienced by 100% of the population.
BeekeeperAI a CHV portfolio - First CHAI-Certified Collaboration Accelerates AI Validation and Adoption for Underserved Populations
May 27, 2025
BeeKeeperAI, a San Francisco, CA-based provider of zero-trust, collaboration software for the development and deployment of artificial intelligence (AI), raised $12.1M in Series A funding.
Sanctuary AI a CHV portfolio - Leads the Industry in Controlling Advanced Hydraulic Hands Using Reinforcement Learning
Apr 1, 2025
Sanctuary AI has revealed a new humanoid robot, shooting for the "world's first human-like intelligence in general purpose robots (GPR). The first commercially available, general-purpose robot of its kind: a 5-foot, 7-inch working machine named Phoenix, is powered by an advanced AI software system called Carbon.
Biotia - A CHV portfolio raises U$8M Series A
Aug 23, 2023
Biotia, a company fighting infectious diseases powered by genomics and artificial intelligence (AI), has raised an oversubscribed $8 million Series A round led by OCA Ventures. OCA, a veteran early stage venture firm operating from Chicago and Palo Alto was joined by other key investors including Continuum Health Ventures, Phoenix Venture Partners, SeedtoB Capital, SK Square Americas, Digital-Dx Ventures, and others. Prior Seed round investors include Falcon II Ventures, Tau Ventures, Hyperplane Venture Capital, Leawood Venture Capital, SpringTide Ventures, and others.
Immunis - A CHV portfolio raises U$10M Series A
Aug 3, 2023
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has closed a $10M Series A First Closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Strategic investor, Continuum Health Ventures, which supports thesis-driven startups at the intersection of health and technology in the digital health and longevity sectors, also joined the round. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy, which is an age, disuse and disease-associated condition experienced by 100% of the population.
BeeKeeperAI Raises $12.1M in Series A Funding
Jun 28, 2023
BeeKeeperAI, a San Francisco, CA-based provider of zero-trust, collaboration software for the development and deployment of artificial intelligence (AI), raised $12.1M in Series A funding.
The round was led by Sante Ventures, with participation from Continuum Health Ventures, the Icahn School of Medicine at Mount Sinai, AIX Ventures, TA Group Holdings, and UCSF.
BeekeeperAI also announced announced the general availability of EscrowAI, a patent-protectedi zero-trust collaboration platform. EscrowAI leverages Azure confidential computing to resolve the challenges of data sovereignty, privacy, and security. In healthcare, EscrowAI enables HIPAA-compliant research on full PHI without exposing the patient data, thereby reducing the AI development timeline dramatically due to streamlined collaboration agreements and access to more precise data.
Sanctuary AI rolls out Phoenix, a Carbon-based humanoid AI labor robot
May 5, 2023
Sanctuary AI has revealed a new humanoid robot, shooting for the "world's first human-like intelligence in general purpose robots (GPR). The first commercially available, general-purpose robot of its kind: a 5-foot, 7-inch working machine named Phoenix, is powered by an advanced AI software system called Carbon.
Phoenix features dexterous hands intended to perform tasks ranging from stocking shelves to unloading a truck to working a register to many healthcare applications.
DeepWell DTx's founder launches Medicinal Media, highlights links between games and healing
May 5, 2023
DeepWell Digital Therapeutics (DTx) cofounder Mike Wilson has started Medicinal Media, a nonprofit group and media publication that highlights the connection between games and healing. The goal is to illuminate the art and science of “beneficial media” with an emphasis on mental health.
